The science behind NeuroAlly™.

Stress science has a blind spot.

For decades, stress research focused on one system: the hormonal axis. Cortisol. Adrenal output. Fight or flight. Every supplement on the market targets this pathway.

But the immune system regulates stress too. Regulatory immune cells influence neural signaling. Inflammatory tone shapes how stress feels. Your body's response to pressure isn't purely hormonal — it's immunological.

NeuroAlly™ engages this immune pathway — the one first characterized in M. vaccae, a soil organism studied by Stanford, Rook, and Lowry across five decades of academic immunology.

Crucially, NeuroAlly™ is not that research strain. It is KGA-10™ — M. petrae — a separate, supplement-grade strain selected as the highest performer through the same mechanism. The mechanism is characterized in preclinical research; our product claims rest on a 60-person randomized, double-blind, placebo-controlled clinical trial of KGA-10™, completed in 2026.

A note on the evidence that follows: the three mechanisms described in the next section are from the M. vaccae academic literature — animal models and in-vitro work. They are the scientific context for the pathway, not direct evidence for any īther product claim. Those claims rest on the 2026 KGA-10™ trial.

A defined molecule.
A canonical receptor.

A 2019 study identified a specific bioactive lipid released by M. vaccae — 10(Z)-hexadecenoic acid (10(Z)-HDA) — that activates PPAR-α, a well-characterized human nuclear receptor central to inflammatory gene regulation. In vitro, the lipid produces a dose-dependent reduction in IL-6.

What the academic literature has explored.

Five behavioral domains studied in animal models by independent academic groups. Listed here as research context only — not a list of īther's product effects. The 2026 RCT measured perceived stress and hs-CRP.